About | HeinOnline Law Journal Library | HeinOnline Law Journal Library | HeinOnline

LOG IN
LOG IN


12 Med. L. Int'l 3 (2012)

handle is hein.journals/medclint12 and id is 1 raw text is: MEDICAL LAW Editorial INTERNATIONAL Medical Law International 12(I) 3-10 Com m ercialization K The Author(s) 2012 Reprints and permission: versus open science sagepub.co.uk/journalsPermissions.nav u o e sDOI: 10.1177/0968533212441887 mli sagepub corn Making sense of the miSAGE OSAGE message(s) in the bottle Shawn HE Harmon University of Edinburgh, UK Timothy Caulfield University of Alberta, Canada Yann Joly McGill University, Canada Abstract Efforts to improve research outcomes have resulted in genomic researchers being confronted with complex and seemingly contradictory instructions about how to per- form their tasks. For example, increasing pressure to commercialise (academic) research is paralleled by pressure to collaborate, share data, and disseminate knowledge quickly so as to encourage scientific progress, maximise research impact, and meet humanitarian goals. This article briefly explores some of the relevant instructions in Canada and the United Kingdom and concludes that commercialisation and more open collaborative practices are not necessarily irreconcilable. They should be viewed as complementary elements of an innovation framework for which more evidence must be gathered with respect to the impact of this coexistence. Keywords open science, data sharing, commercialisation, translation, technology transfer, stem cell, genome, academic research, innovation, genomics research Corresponding author: Timothy Caulfield, Health Law and Science Policy Group, Law Centre, University of Alberta, Edmonton, AB, T6G 2H5, UK Email: tcaulfld@law.ualberta.ca